Evidence map›Paper›PMID 32727526›Full record

SynthesisCritical care (London, England)2020

Efficacy of convalescent plasma for the treatment of severe influenza.

Zhiheng Xu, Jianmeng Zhou, Yongbo Huang, Xuesong Liu, Yonghao Xu, Sibei Chen, Dongdong Liu, Zhimin Lin, Xiaoqing Liu, Yimin Li

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Hyperimmune immunoglobulin for people with COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Review
  15. Review
  16. COVID-19, Hypercoagulability, and Cautiousness with Convalescent Plasma.American journal of respiratory and critical care medicine · 2021
    Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zhiheng XuState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China.
Jianmeng ZhouState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China.
Yongbo HuangState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China.
Xuesong LiuState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China.
Yonghao XuState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China.
Sibei ChenState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China.
Dongdong LiuState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China.
Zhimin LinState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China.
Xiaoqing LiuState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China. lxq1118@126.com.
Yimin LiState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine, 151 Yanjiang Street, West Guangzhou, 510120, Guangdong, China. dryiminli@vip.163.com.
State Key Laboratory of Respiratory Disease · CNFirst Affiliated Hospital of Guangzhou Medical University · CNGuangzhou Medical University · CN

Funding

National Natural Science Foundation of China 81970071the National Science and Technology Major Project 2017ZX10204401the Special Project for Emergency of the Ministry of Science and Technology 2020YFC0841300the Special Project of Guangdong Science and Technology Department 2020B111105001
6 · The paper itself

Abstract

backgroundConvalescent plasma administration may be of clinical benefit in patients with severe influenza, but reports on the efficacy of this therapy vary.

methodsWe conducted a systematic review and meta-analysis assessing randomized controlled trials (RCTs) involving the administration of convalescent plasma to treat severe influenza. Healthcare databases were searched in February 2020. All records were screened against eligibility criteria, and the risks of bias were assessed. The primary outcome was the fatality rate.

resultsA total of 2861 studies were retrieved and screened. Five eligible RCTs were identified. Pooled analyses yielded no evidence that using convalescent plasma to treat severe influenza resulted in significant reductions in mortality (odds ratio, 1.06; 95% CI, 0.51-2·23; P = 0.87; I

conclusionsThe administration of convalescent plasma appears safe but may not reduce the mortality, number of days in the intensive care unit, or number of days on mechanical ventilation in patients with severe influenza.

Indexed as

COVID-19COVID-19 SerotherapyHumansImmunization, PassiveInfluenza, HumanOdds RatioConvalescent plasmaEfficacyMeta-analysisSevere influenza

Identifiers

PMID32727526
PMCPMC7388480
OpenAlexW3045917100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.